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BACKGROUND
The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is 
vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
Within a year, several vaccines have been developed and millions of doses delivered. 
Reporting of adverse events is a critical postmarketing activity.
METHODS
We report findings in 23 patients who presented with thrombosis and thrombo-
cytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vac-
cine (AstraZeneca). On the basis of their clinical and laboratory features, we iden-
tify a novel underlying mechanism and address the therapeutic implications.
RESULTS
In the absence of previous prothrombotic medical conditions, 22 patients pre-
sented with acute thrombocytopenia and thrombosis, primarily cerebral venous 
thrombosis, and 1 patient presented with isolated thrombocytopenia and a hemor-
rhagic phenotype. All the patients had low or normal fibrinogen levels and elevat-
ed d-dimer levels at presentation. No evidence of thrombophilia or causative 
precipitants was identified. Testing for antibodies to platelet factor 4 (PF4) was 
positive in 22 patients (with 1 equivocal result) and negative in 1 patient. On the 
basis of the pathophysiological features observed in these patients, we recommend 
that treatment with platelet transfusions be avoided because of the risk of progres-
sion in thrombotic symptoms and that the administration of a nonheparin antico-
agulant agent and intravenous immune globulin be considered for the first occur-
rence of these symptoms.
CONCLUSIONS
Vaccination against SARS-CoV-2 remains critical for control of the Covid-19 pan-
demic. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin 
therapy, can occur after the administration of the ChAdOx1 nCoV-19 vaccine. 
Rapid identification of this rare syndrome is important because of the therapeutic 
implications.
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Coronavirus disease 2019 (Covid-19) has been associated with considerable morbidity and mortality.1,2 From the on-
set of the Covid-19 pandemic to March 2021, 
more than 126.8 million cases and 2.7 million 
deaths were documented worldwide.3
With unprecedented speed, vaccines against 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) have been licensed and used 
worldwide.4,5 Rollout of the vaccines has been 
uneven, but in some countries, very high levels 
of coverage have been achieved. In Israel, more 
than half the population of 9 million has re-
ceived a second dose; in the United Kingdom, 
more than 25 million people have received at 
least one dose. With such widespread and rapid 
uptake of the vaccines, safety signals should be 
documented.
A safety signal of particular concern tempo-
rally associated with the administration of the 
ChAdOx1 nCoV-19 vaccine (AstraZeneca) has 
recently been described,6,7 involving an unusual 
clinical constellation of abnormal clotting, par-
ticularly cerebral venous thrombosis, and throm-
bocytopenia that has resulted in death in some 
cases. Intensive reviews of the risk of venous 
thromboembolism associated with vaccines 
against SARS-CoV-2 were conducted by both the 
U.K. Medicines and Healthcare Products Regula-
tory Agency (MHRA) and the European Medi-
cines Agency (EMA). After their initial reviews, 
both agencies confirmed that the risk of venous 
thromboembolism associated with the vaccines 
was not higher than the background risk in the 
general population and emphasized the over-
whelmingly favorable risk–benefit ratio for vac-
cines against SARS-CoV-2. However, although a 
causal association has not yet been confirmed,8 
they have acknowledged that vaccines against 
SARS-CoV-2 may be associated with a rare but 
serious adverse event related to thrombosis, pri-
marily cerebral venous thrombosis, and throm-
bocytopenia.9
To gain a better understanding of the de-
scribed clinical syndrome of concern, we con-
ducted a study involving 22 patients referred to 
a specialist hematologist for the evaluation of 
thrombosis and thrombocytopenia and 1 patient 
referred for the evaluation of isolated thrombo-
cytopenia and a very high d-dimer level tempo-
rally associated with the administration of the 
first dose of the ChAdOx1 nCoV-19 vaccine. The 
thrombosis events were primarily cerebral ve-
nous thrombosis but also included arterial 
thrombosis and more common types of venous 
thromboembolism, such as pulmonary embo-
lism. We identified a novel underlying mecha-
nism associated with the presentation. On the 
basis of the clinical features and subsequent 
laboratory findings, we propose an altered ther-
apeutic approach and give guidance on the as-




Patients were identified for the investigation of 
suspected vaccine-induced thrombosis and 
thrombocytopenia (i.e., vaccine-induced immune 
thrombotic thrombocytopenia, or VITT). No 
evidence of hereditary or acquired thrombo-
philia had been identified at the referring hospi-
tals. In the 3 index patients, the decision to test 
for antibodies to platelet factor 4 (PF4) was 
based on the presence of progressive thrombo-
sis, thrombocytopenia, and clinical features 
similar to those seen in patients with heparin-
induced thrombocytopenia (HIT), despite the 
absence of exposure to heparin. Within less than 
7 days, a total of 23 patients were identified for 
testing, including new patients who were admit-
ted with suggestive clinical features and 3 pa-
tients who had died after a clinical course con-
sistent with this syndrome.
Enzyme-Linked Immunosorbent Assays
Testing for anti-PF4 antibodies was performed 
by means of enzyme-linked immunosorbent as-
says (ELISAs) at six reference laboratories in the 
United Kingdom. Additional testing for anti-PF4 
antibodies was performed by means of various 
techniques used locally for HIT testing at indi-
vidual centers. In many cases, HIT testing with 
the chemiluminescence HemosIL AcuStar HIT 
IgG assay (Werfen) was negative but testing with 
an ELISA was positive. ELISAs included the Life-
codes PF4 IgG assay (Immucor) and the Assera-
chrom HPIA IgG assay (Stago). These assays 
have a normal range (median plus standard de-
viation) of anti-PF4 antibodies for healthy con-
trols and a range for patients who have received 
heparin. The positive thresholds were based on 
the normal ranges (≤0.238 optical density units 
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[OD] for the Asserachrom HPIA IgG assay and 
<0.40 OD for the Lifecodes PF4 IgG assay).10
Functional HIT Assay
In several cases, the ELISA results were confirmed 
by means of a functional HIT assay (HITAlert, 
Diapharma) performed at a reference laboratory 
in accordance with the manufacturer’s instruc-
tions.11 In brief, platelet-rich plasma was pre-
pared from blood samples obtained from volun-
teer donors with group O blood. The platelet-rich 
plasma was incubated in five tubes that con-
tained the following substances: calcium iono-
phore, heparin (0.3 U per milliliter), patient se-
rum, patient serum plus heparin (0.3 U per 
milliliter), and patient serum plus an excess of 
heparin (100 U per milliliter). A previously tested 
serum sample from a patient with a confirmed 
diagnosis of HIT was used as a positive control 
(Fig. 1A). A positive threshold of more than 8% 
platelet activation was applied in accordance 
with the manufacturer’s recommendations, pro-
viding a sensitivity of 78% and specificity of 98% 
when used to confirm the diagnosis of HIT. 
Data were analyzed with the use of a flow cy-
tometer (CytoFlex, Beckman Coulter).
Additional Serologic and Antibody Tests
A multiplexed electrochemiluminescence assay 
(Meso Scale Discovery) was used, as described 
previously,12 to measure serum levels of antibod-
ies to SARS-CoV-2 antigens, including spike pro-
tein, receptor-binding domain (RBD), and nucleo-
capsid protein; levels of functional antibodies 
that inhibit the interaction of angiotension-con-
verting–enzyme 2 (ACE2)–receptor protein with 
spike protein and RBD of SARS-CoV-2; and levels 
of antibodies to spike protein of seasonal corona-




Among the 23 patients included in this study, 
the median age was 46 years (range, 21 to 77), 
with 16 patients (70%) younger than 50 years. 
Fourteen patients (61%) were female. All the 
patients were reported as previously fit and well 
by referring hospitals, with no history of a 
medical condition or use of a medication likely 
to precipitate thrombosis, except for 1 patient 
who had a history of deep venous thrombosis 
and 1 patient who was known to be taking the 
combined oral contraceptive pill. All the patients 
had received the first dose of the ChAdOx1 
nCoV-19 vaccine 6 to 24 days (median, 12 days) 
before presentation. Mild bruising and petechiae 
were evident in some patients. Secondary cere-
bral hemorrhage was noted in some patients 
who had cerebral venous thrombosis. The 1 pa-
tient who did not present with thrombosis had 
clinically significant bruising but no other hem-
orrhagic manifestations.
The clinical and laboratory features of the 
patients are summarized in Table 1. Of the 22 
patients who presented with thrombosis, 13 had 
clinical features consistent with cerebral venous 
thrombosis (1 with concurrent acute portal vein 
thrombosis and pulmonary embolism), 4 had 
pulmonary embolism (1 with concurrent deep 
venous thrombosis), 1 had deep venous throm-
bosis and bilateral adrenal hemorrhage, 2 had 
an ischemic stroke affecting the middle cerebral 
artery territory, and 2 had portal vein thrombo-
sis (1 with concurrent acute myocardial infarc-
tion and 1 with evidence of concurrent acute 
aortic thrombosis on imaging). Additional throm-
bosis events associated with progression occurred 
in patients who received platelet transfusions or 
heparin-based therapy at presentation. Within 
the entire cohort, 7 patients (30%) died. Results 
of a postmortem evaluation, available for 1 pa-
tient, showed evidence of thrombosis in many 
small vessels, especially vessels in the lungs and 
intestine, cerebral veins, and venous sinuses, as 
well as evidence of extensive intracerebral hem-
orrhage.
Laboratory Testing
All the patients had a negative SARS-CoV-2 
polymerase-chain-reaction assay at presentation 
(data not shown). The 10 patients with samples 
available for testing had a negative SARS-CoV-2 
serologic test for antibodies to nucleocapsid pro-
tein, a finding that ruled out recent exposure to 
SARS-CoV-2. In all 10 patients, levels of antibod-
ies to spike protein and RBD of SARS-CoV-2 
were within the range seen in recipients of one 
dose of the ChAdOx1 nCoV-19 vaccine, and levels 
of antibodies to seasonal coronaviruses were 
within the range seen in recipients of the 
ChAdOx1 nCoV-19 vaccine and in the general 
population. Levels of functional antibodies that 
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inhibit the interaction of ACE2-receptor protein 
with spike protein and RBD of SARS-CoV-2 were 
also within the range seen in recipients of one 
dose of the ChAdOx1 nCoV-19 vaccine (Goldblatt 
D: personal communication).
Thirteen patients had low fibrinogen levels as 
determined with the method of Clauss (range, 
0.3 to 4.5 g per liter; normal range, 1.5 to 4.0). 
The d-dimer levels were much higher than would 
be expected in patients with acute venous throm-
boembolism (median, 31,301 fibrinogen-equiva-
lent units [FEU]; range, 5000 to 80,000). No 
other relevant laboratory tests were positive, in-
cluding tests for thrombophilia, antinuclear anti-
bodies, extractable nuclear antigen, and antiphos-
pholipid antibodies (data not shown). A test for 
lupus anticoagulant was positive in 5 of the 10 
patients for whom results were available, but in 
the context of severe coagulopathy and negative 
tests for anticardiolipin antibodies and anti–β2-
glycoprotein 1b antibodies, these results were 
considered to be unreliable.
In all 23 patients, the ELISA for anti-PF4 an-
tibodies was performed on a sample obtained 
before the administration of heparin-based ther-
apy. Although HIT testing with the HemosIL 
AcuStar HIT IgG assay was negative in all 9 pa-
tients who were tested, an ELISA for anti-PF4 
antibodies was positive in 22 of the 23 patients. 
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cination with cerebral venous thrombosis, 
thrombocytopenia, and a high d-dimer level and 
was not clinically distinguishable from the re-
maining cohort — had a negative ELISA (Life-
codes PF4 IgG assay) and functional HIT assay. 
However, the tested sample had been obtained 
5 days after presentation, after the patient had 
received several platelet transfusions. Another 
patient — who presented 12 days after vaccina-
tion with deep venous thrombosis and bilateral 
adrenal hemorrhage but with a high d-dimer 
level and a low fibrinogen level, with no evi-
dence of an alternative diagnosis — had an 
equivocal result on the ELISA (a level of 0.156 
OD on the Asserachrom HPIA IgG assay).
A functional HIT assay performed to confirm 
the ELISA result was positive in 5 of the 7 pa-
tients who were tested. These findings confirmed 
the presence of platelet activation similar to that 
seen in patients with HIT (Fig. 1B), as measured 
by the addition of donor platelets to patient se-
rum in the absence of heparin. This effect was 
not increased with the addition of heparin in 
physiologic doses but was fully suppressed with 
the addition of an excess of heparin. A summary 
of our recommendations for testing and treat-
ment, based on our current understanding of the 
syndrome, is shown in Figure 2.
Discussion
The rapid approval and subsequent global rollout 
of vaccines against SARS-CoV-2 has inevitably 
resulted in reports of adverse events after receipt 
of the vaccine. Most adverse events reported thus 
far have been associated with risks similar to 
background risks in the general population and 
have not raised concerns. However, for very rare 
events with complex diagnostic algorithms, the 
background risks may be difficult to measure or 
interpret.
We report the detection of anti-PF4 antibod-
ies, unrelated to the use of heparin therapy, in a 
mostly young, generally healthy cohort of pa-
tients presenting with acute atypical thrombosis, 
primarily involving the cerebral veins, and con-
current thrombocytopenia. All the patients had 
d-dimer levels at presentation that were much 
higher than would be expected in patients with 
acute venous thromboembolism13 and are typi-
cally seen in patients with cancer.14 The very 
conservative d-dimer cutoff used in our algo-
rithm, of 4000 FEU, was chosen to ensure that 
cases were not missed and were considered for 
further testing, because there is a possibility 
that a spectrum of severity in this syndrome 
could be missed otherwise. In all the patients, 
manifestations occurred 6 to 24 days after the 
administration of the first dose of the ChAdOx1 
nCoV-19 vaccine.
HIT is a progressive thrombotic condition 
that can cause both venous and arterial throm-
bosis, typically 5 to 14 days after exposure to 
heparin. It is more common in female patients, 
particularly those who receive unfractionated 
heparin during cardiac surgery, as well as in 
patients who receive heparin after surgery, espe-
cially cardiac and orthopedic procedures.15 Diag-
nosis is confirmed by the presence of anti-PF4 
antibodies.16,17
Figure 1 (facing page). Flow Cytometric Analysis of  
Results of a Functional HIT Assay in a Control Patient 
and a Patient in the Study.
Shown is the flow cytometric analysis of results of a 
functional heparin-induced thrombocytopenia (HIT) 
assay (HITAlert, Diapharma) performed on a serum 
sample from a control patient with a confirmed diagno-
sis of HIT (Panel A) and on a serum sample from a pa-
tient included in the study (Panel B). Platelets from a 
volunteer donor with group O blood are incubated in 
five tubes containing the following substances: calcium 
ionophore, heparin (0.3 U per milliliter), patient serum, 
patient serum plus heparin (0.3 U per milliliter), and 
patient serum plus an excess of heparin (100 U per mil-
liliter). In the analysis of the control sample (Panel A), 
donor platelets show reactivity in the presence of calci-
um ionophore, with 98% of platelets positive for both 
anti–CD41–PE and anti–annexin V–FITC conjugated 
antibodies (data are shown in the upper right quadrant 
of each plot); reduced reactivity in the presence of hep-
arin (0.3 U per milliliter), with only 0.6% of CD41-posi-
tive platelets also positive for annexin V; reduced reac-
tivity in the presence of patient serum, with only 0.5% 
of platelets activated; reactivity in the presence of pa-
tient serum plus heparin (0.3 U per milliliter), with 41% 
of platelets activated; and reduced reactivity in the 
presence of patient serum plus an excess of heparin 
(100 U per milliliter), with 0.4% of platelets activated, 
as compared with 41% with patient serum plus heparin 
in a physiologic dose. In the analysis of the study sam-
ple (Panel B), donor platelets show reactivity in the 
presence of patient serum, with 55% of platelets acti-
vated; reactivity in the presence of patient serum plus 
heparin (0.3 U per milliliter), with 37% of platelets acti-
vated; and reduced reactivity in the presence of patient 
serum plus an excess of heparin (100 U per milliliter), 
with 1% of platelets activated. FITC denotes fluorescein 
isothiocyanate, and PE phycoerythrin.
n engl j med nejm.org 6
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Data describing the rare detection of patho-
logic anti-PF4 antibodies unrelated to the use of 
heparin therapy are limited.18,19 Furthermore, the 
analysis of anti-PF4 antibodies appears to be 
specific to the given assay. In our study, confir-
mation of ELISA results for anti-PF4 antibodies 
was undertaken with the use of a functional HIT 
assay. The clinical features of this vaccine-induced 
syndrome are more typical of those seen in pa-
tients with HIT who have early reexposure to 
heparin, including severe thrombocytopenia, ag-
gressive thrombosis, and disseminated intravas-
cular coagulation.20
The risk of thrombocytopenia and the risk of 
venous thromboembolism after vaccination 
against SARS-CoV-2 do not appear to be higher 
than the background risks in the general popu-
lation, a finding consistent with the rare and 
sporadic nature of this syndrome. Furthermore, 
headaches, fevers, and muscle aches have occurred 
after vaccination for 48 to 72 hours in some pa-
tients. The events reported in this study appear to 
be rare, and until further analysis is performed, 
it is difficult to predict who may be affected. 
The symptoms developed more than 5 days af-
ter the first vaccine dose, reflecting an immu-
nologic pattern similar to that of HIT.
We have identified a novel mechanism and 
pathophysiological basis that prompts careful 
consideration of treatment. Avoidance of platelet 
transfusions is critical, because such treatment 
would provide a substrate for further antibody-
mediated platelet activation and coagulopathy. 
The exact nature of these pathologic antibodies 
has not been characterized, but they appear to 
be of the IgG subtype, and platelet activation can 
be completely abrogated with an excess of hepa-
rin, as seen in classic HIT. Identification of the 
mechanism through which the vaccine could 
trigger the formation of these pathologic anti-
bodies would require further study. An under-
standing of the precise pathophysiological mech-
anism may allow for more targeted therapeutic 
interventions.
Although evidence does not yet suggest that 
the use of heparin will exacerbate this condition, 
pending further data, we would recommend 
considering anticoagulation with the use of a non-
heparin anticoagulant agent, such as argatro-
ban, danaparoid, fondaparinux, or direct oral 
anticoagulants. Intravenous immune globulin 
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ment of patients with “spontaneous” autoimmune 
HIT, which is the closest comparison to this 
vaccine-induced syndrome, and IVIG would be 
expected to have direct antibody-mediated toxic 
effects.21-23 Plasma exchange with plasma rather 
than albumin could also be effective in tempo-
rarily reducing levels of pathologic antibodies 
and providing some correction of the coagulopa-
thy in terms of the hypofibrinogenemia.
A suggested algorithm for identification of 
vaccine-induced thrombosis and thrombocyto-
penia is presented and can be adapted as we 
generate further information. The combination 
of thrombosis and an apparent consumptive 
coagulopathy poses a dilemma with respect to 
the benefits and risks associated with aggressive 
anticoagulation. This dilemma is especially rel-
evant in patients with cerebral venous thrombosis, 
Figure 2. Suggested Algorithm for Testing and Treatment of Patients Presenting with Thrombosis and Thrombocyto-
penia 5 to 30 Days after Vaccination.
The HemosIL AcuStar HIT IgG assay is not recommended for the evaluation of suspected vaccine-induced throm-
bosis and thrombocytopenia. ELISA denotes enzyme-linked immunosorbent assay, FEU fibrinogen-equivalent units, 
HIT heparin-induced thrombosis, and IVIG intravenous immune globulin.
Refer to hematologist
Patient presents with acute thrombosis









Consider use of glucocorticoids
Administer nonheparin anticoagulant
Consider treatment to increase 
fibrinogen level to >1.0 g/liter
D-dimer level, >4000 FEU
Low or normal fibrinogen level
No evidence of alternative diagnosis
Review diagnosis and treatment
Consider alternative or functional
HIT assay
Continue treatment
Perform tests for prothrombin time,
activated partial thromboplastin time,
fibrinogen level, and D-dimer level
Positive Negative
D-dimer level, <2000 FEU
Normal results of coagulation tests
and fibrinogen level
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in whom bleeding could be catastrophic but 
withholding anticoagulation could be equally 
harmful. It is unclear whether delaying aggres-
sive anticoagulation until after initial disease 
control with IVIG or plasma exchange is war-
ranted, but mortality among patients with cere-
bral venous thrombosis appears to be higher 
than expected, so early treatment decisions are 
likely to be critical. There is no evidence that 
heparin alternatives are required; however, in view 
of the similarity of this syndrome to conven-
tional HIT, alternatives could be considered un-
til further data are available.
In all cases reported to date, this syndrome 
of thrombocytopenia and venous thrombosis ap-
pears to be triggered by receipt of the first dose 
of the ChAdOx1 nCoV-19 vaccine. Although there 
have been a few reports of patients with symp-
toms consistent with this clinical syndrome after 
the receipt of other vaccines against SARS-CoV-2, 
none have yet been confirmed to fulfill the diag-
nostic criteria, specifically the presence of throm-
bocytopenia, thrombosis, a very high d-dimer 
level, and a low or normal fibrinogen level. 
Furthermore, in Israel, where two doses of the 
BNT162b2 vaccine (Pfizer–BioNTech) have been 
provided to more than 4 million people, no 
cases of this rare syndrome have been reported. 
Although natural SARS-CoV-2 infection has been 
associated with thromboembolic phenomena, 
those events differ from the specific syndrome 
described in this study.
The risk of Covid-19 remains a serious public 
health consideration worldwide, and vaccination 
against SARS-CoV-2 provides critical protection.24 
There is a substantial risk of ascertainment bias 
when associating adverse clinical events with 
vaccination; however, the syndrome described in 
this study has a combination of clinical and labo-
ratory features that is exceptional and has not 
been previously observed by any of the authors 
who are specialist hematologists or neurologists. 
Ongoing data collection and studies could help 
to establish whether and how the development 
of pathologic platelet-activating anti-PF4 anti-
bodies, unrelated to the use of heparin therapy, 
could be associated with vaccination against 
SARS-CoV-2.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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